[Pubmed] Inebilizumab Treatment in a Patient with Co-occurring AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

[RSS-Bot]

Neurology. 2025 Apr 8;104(7_Supplement_1):4271. doi: 10.1212/WNL.0000000000211562. Epub 2025 Apr 7.

ABSTRACT

OBJECTIVE: This study aims to delineate the clinical features underlying the concurrent of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), and to identify efficacious therapeutic strategies.

BACKGROUND: NMOSD and MG are uncommon autoimmune diseases that infrequently co-exist. Despite previous reports, a consensus on treating NMOSD concurrent with MG is lacking.

DESIGN/METHODS: We present the case of a 55-year-old female with both anti-aquaporin-4 (AQP4) antibody-positive NMOSD and anti-acetylcholine receptor (AChR) antibody-positive MG, who achieved stable disease control following treatment with inebilizumab without significant adverse effects. We also conducted a literature review to evaluate the clinical profile of this comorbidity.

RESULTS: Our review identified 85 patients with concurrent NMOSD and MG. In 70 well-documented cases, MG predated NMOSD in 60 (85.8%) cases, with 42 (70%) patients having undergone thymectomy. NMOSD was the initial diagnosis in 6 (8.6%) cases, with thymectomy performed in 2 (33.3%). For NMOSD treatment, although most patients received steroid hormones and immunosuppressive agents, quite a few patients had persistent severe disability. Additionally, Of 44 patients with clear records of disease recurrence, 31 (70.5%) patients experienced frequent relapses of optic neuritis and myelitis, ranging from 1 to 15 attacks, averaging five. Our patient treated with inebilizumab for 1 year and no relapse was recorded to date.

CONCLUSIONS: Though MG typically precedes NMOSD and thymectomy is frequently performed, it is not a prerequisite for NMOSD development but may represent a potential risk factor. MG generally follows a benign course, in contrast to the more aggressive nature of NMOSD. The utility of biological agents such as ineblizumab for patients with both NMOSD combined with MG warrants further attention. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Ms. Song has nothing to disclose. Author has nothing to discloseAuthor has nothing to disclose.

PMID:40194236 | DOI:10.1212/WNL.0000000000211562


Source: https://pubmed.ncbi.nlm.nih.gov/4019423 ... t9+e462414